Which companies overlap with Centro Universitario de Ciencias de la Salud, Mexico's portfolio?

Top competitors by shared drug class: Ain Shams University, AJU Pharm Co., Ltd., Aciex Therapeutics, Inc., Abbott, AceLink Therapeutics, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/centro-universitario-de-ciencias-de-la-salud-mexico.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Centro Universitario de Ciencias de la Salud, Mexico — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Centro Universitario de Ciencias de la Salud, Mexico pipeline: 2 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Losartan and Amlodipine	Losartan and Amlodipine	marketed	Angiotensin II receptor antagonist + Calcium channel blocker combination	AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)	Cardiovascular
green tea extract	green tea extract	marketed	Botanical extract / Polyphenol antioxidant		Oncology, Cardiovascular, Metabolic, General wellness
Dapagliflozin Pill	Dapagliflozin Pill	phase 3	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)	Diabetes
Empagliflozin Pill	Empagliflozin Pill	phase 3	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)	Diabetes
Calcined magnesia	Calcined magnesia	phase 3	Antacid and osmotic laxative		Gastroenterology

Therapeutic area mix

Diabetes · 2
Cardiovascular · 1
Gastroenterology · 1
Oncology, Cardiovascular, Metabolic, General wellness · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ain Shams University · 2 shared drug classes
AJU Pharm Co., Ltd. · 1 shared drug class
Aciex Therapeutics, Inc. · 1 shared drug class
Abbott · 1 shared drug class
AceLink Therapeutics, Inc. · 1 shared drug class
Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
AO GENERIUM · 1 shared drug class
ADvantage Therapeutics · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Centro Universitario de Ciencias de la Salud, Mexico:

Cite this brief

Drug Landscape (2026). Centro Universitario de Ciencias de la Salud, Mexico — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centro-universitario-de-ciencias-de-la-salud-mexico. Accessed 2026-05-18.